

From :  
The Drugs Controller General (India)  
Directorate General of Health Services

FDA Bhawan, New Delhi  
Dated

19 JAN 2012

To,

M/S. Allergan India Pvt Limited  
KSEF Building Opp.Kims Hospital,  
Kondoji, Basappa road,  
Kalasipalyam, Bangalore-560002

Sub: -Registration of M/S. Allergan Sales LLC, 8301, Mars Drive, Waco, Texas, 76712, USA under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

FF-130

Dear Sir,

Please refer to your application no. NIL dated 23/12/2011, received by this Office vide diary no. 59193 dated 27/12/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

8. This registration in no way relieves you of the responsibility of complying with all other provisions of the Drugs & Cosmetics Act and Rules there under, and any other provisions of any other Act and Rules applicable in the matter concerned.
9. Each consignment of the drugs to be imported by you shall be accompanied by a test / analysis reports.
10. Based on this registration, import applications for the drug (s) endorsed in the enclosed Registration Certificate shall be considered for the issue of Form 10 Licence under the Rules.
11. This Registration Certificate is being issued under the condition that during the pendency of Registration, the applicant may be required to deposit inspection fee as stipulated under Clause (5) of Rule 24-A and enable inspection of manufacturing site by the officials authorised for this purpose. Non-compliance to this condition as and when so directed would result in cancellation of Registration Certification.

Please note that Registration Certificate issued is liable to be suspended / cancelled, if any of the condition stipulated above is not complied with, apart from any other condition that may be taken under the provisions of the Drugs & Cosmetics Act, 1940 and the Rules there under.

Please acknowledge the receipt.

OFFICE COPY

Yours faithfully,

V. G. S.

Drugs Controller General (India)

**Copy forwarded to:**

1. The Assistant Drug Controller (I), New Custom House, Annexe, Ballard Estate, Fort, Mumbai-400038.
2. The Assistant Drug Controller (I), 15/1, Strand Road, Custom House, Kolkata-700001.
3. The Assistant Drug Controller (I), Room No. 66, 2<sup>nd</sup> Floor, Custom House, Chennai-600001.
4. The Assistant Drug Controller (I), Jawaharlal Nehru Port, Trust Nhava Seva Port, Raigard, Maharashtra.
5. The Assistant Drug Controller (I), International Air Cargo Complex, Indira Gandhi International Air Port, New Delhi-110037.



**GOVERNMENT OF INDIA**  
**Central Drugs Standard Control Organisation**  
**Ministry of Health & Family Welfare**  
**FDA BHAWAN, NEW DELHI (INDIA)**

Form 41

(See Rule 27-A)

**REGISTRATION CERTIFICATE**

Registration Certificate issued for import of drugs into India

Under Drugs and Cosmetics Rules, 1945

Registration Certificate No. FF-130

19 JAN 2012 Dated

1. M/S. Allergan Sales LLC, 8301, Mars Drive, Waco, Texas, 76712, USA having factory premises at M/s. Allergan Sales LLC, 8301, Mars Drive, Waco, Texas, 76712, USA has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s) which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/03/2012 to 28/02/2015 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S Allergan India Pvt Limited KSEF Building Opp.Kims Hospital, Kondoji, Basappa road, Kalasipalyam, Bangalore-560002 who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date: \_\_\_\_\_

19 JAN 2012



LICENSING AUTHORITY

Seal/Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health & Family Welfare  
FDA Bhawan, Kolla Road, I.T.O.  
New Delhi - 110 002

Conditions of the Registration Certificate

1. The Registration Certificate shall be displayed at a prominent place by the authorised agent.
2. No drug shall be registered unless it has a free sale approval in the country of origin, and/or in other major countries.
3. The manufacturer or his authorised agent in India shall comply with the conditions of the import licence issued under the Drugs and Cosmetics Rules, 1945.
4. The manufacturer or his authorised agent in India shall inform the licensing authority forthwith in the event of any administrative action taken due to adverse reaction, viz. market withdrawal, regulatory restrictions, or cancellation of authorisation, and/or not of standard quality report of any drug pertaining to this Registration Certificate declared by the Regulatory Authority of the country of origin or by any Regulatory Authority of any other country, where the drug is marketed/sold or distributed. The despatch and marketing of the drug in such cases shall be stopped immediately, and the licensing authority shall be informed immediately. Further action in respect of such stopped marketing of drug shall be followed as per the direction of the licensing authority. In such cases, action equivalent to that taken with reference to the concerned drug in the country of origin or in the country of marketing shall be followed in India also, in consultation with the licensing authority. The licensing authority may, however, direct any further modification to this course of action, including the withdrawal of the drug from Indian market within 48 hours time period.
5. The manufacturer or his authorised agent in India shall inform the licensing authority within 30 days in writing in the event of any change in manufacturing process, or in packaging, or in labelling or in testing, or in documentation of any of the drug pertaining to this Registration Certificate. In such cases, where there shall be any major change/modification in manufacturing, or in processing or in testing, or in documentation as the case may be, at the discretion of the licensing authority, the manufacturer or his authorised agent in India shall obtain necessary approval within 30 days by submitting a separate application along with the registration fee, as specified in clause (ii) of sub rule (3) of rule 24-A.
6. The manufacturer or his authorised agent in India shall inform the licensing authority immediately in writing in the event of any change in the constitution of the firm and /or address of the registered office/ factory premises operating under this Registration Certificate. Where any such change in the constitution of the firm and/or address takes place, the current Registration Certificate shall be deemed to be valid for a maximum period of three months from the date on which the change has taken place unless, in the meantime, a fresh Registration Certificate has been taken from the licensing authority in the name of the firm with the changed constitution of the firm and/or changed address of the registered office or factory premises".



F.No. 6-4/FF/130/02-DC(RE REG 2012)

GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation  
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED  
UNDER REGISTRATION CERTIFICATE NO. FF-130  
DATED

19 JAN 2012

1. Ketorolac Tromethamine Ophthalmic Solution  
Each ml contains:  
Ketorolac Tromethamine IP.....0.45%
2. Bimatopost Ophthalmic Solution  
Each ml contains:  
Bimatoprost.....0.03%
3. Cyclosporine Eye Drops 0.5mg/ml
4. Bimatoprost Ophthalmic Solution With sterile Disposable Applicator
5. Gatifloxacin Ophthalmic Solution  
Each ml Contains:  
Gatifloxacin Sesquihydrate  
Equivalent To Gatifloxacin IP.....0.5%w/v

ITEMS (FIVE) ONLY

Place: New Delhi


Date: 19 JAN 2012



V.G.S.  
LICENSING AUTHORITY

Seal/Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health & Family Welfare  
FDA Bhawan, Kotla Road, I.T.O.  
New Delhi-110 002



**F. No. 6-4/FF/34/2011-DC**

**From:**  
The Drugs Controller General (India)  
Directorate General of Health Services

FDA Bhawan, New Delhi

Dated:

To,

**19 JAN 2012**

M/S. Besins Healthcare India Pvt. Ltd.  
Gala No. 7 & 8, 1<sup>st</sup> Floor, Building No.B6,  
Shree Arihant Compound, kalher,  
Bhiwandi,  
Dist. Thane - 421302

**Sub: -Registration of M/s. Besins Manufacturing Belgium, Groot-Bijgaardenstraat 128, 1620 Drogenbos Belgium under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India.**

**FF-616**

Dear Sir,

Please refer to your application no. Nil, dated 06/12/2011, received by this office vide diary no. 57080, dated 13/12/2011, on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall conform to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 Challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

8. This registration in no way relieves you of the responsibility of complying with all other provisions of the Drugs & Cosmetics Act and Rules there under, and any other provisions of any other Act and Rules applicable in the matter concerned.
9. Each consignment of the drugs to be imported by you shall be accompanied by a test / analysis reports.
10. Based on this registration, import applications for the drug (s) endorsed in the enclosed Registration Certificate shall be considered for the issue of Form 10 Licence under the Rules.
11. CDTL test report for three lots/batches for each drug product is required to submit this office before issue of Import license.
12. This Registration Certificate is being issued under the condition that during the pendency of Registration, the applicant may be required to deposit inspection fee as stipulated under Clause (5) of Rule 24-A and enable inspection of manufacturing site by the officials authorised for this purpose. Non-compliance to this condition as and when so directed would result in cancellation of Registration Certification.

Please note that Registration Certificate issued is liable to be suspended / cancelled, if any of the condition stipulated above is not complied with, apart from any other condition that may be taken under the provisions of the Drugs & Cosmetics Act, 1940 and the Rules there under.

Please acknowledge the receipt.

Yours faithfully,

V.G.L.

Drugs Controller General (India)

Copy forwarded to:

1. The Assistant Drug Controller (I), New Custom House, Annexe, Ballard Estate, Fort, Mumbai-400038.
2. The Assistant Drug Controller (I), 15/1, Strand Road, Custom House, Kolkata-700001.
3. The Assistant Drug Controller (I), Room No. 66, 2<sup>nd</sup> Floor, Custom House, Chennai-600001.
4. The Assistant Drug Controller (I), Jawaharlal Nehru Port, Trust Nhava Seva Port, Raigard, Maharashtra.
5. The Assistant Drug Controller (I), International Air Cargo Complex, Indira Gandhi International Air Port, New Delhi-110037.



**GOVERNMENT OF INDIA**  
**Central Drugs Standard Control Organisation**  
**Ministry of Health & Family Welfare**  
FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

**REGISTRATION CERTIFICATE**

*Registration Certificate issued for import of drugs into India*

*Under Drugs and Cosmetics Rules, 1945*

Registration Certificate No. FF-616

**19 JAN 2012** <sup>Dated</sup>

1. M/S. Besins Manufacturing, Belgium having factory premises at M/s. Groot-Bijgaardenstraat 128, 1620, Drogenbos Belgium has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/01/2012 to 31/12/2014 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S Besins Healthcare India Pvt. Ltd. Gala No. 7 & 8, 1<sup>st</sup> Floor, Building No.B6, Shree Arihant Compound, Kalher, Bhiwandi Dist. Thane- 421302, who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date: **19 JAN 2012**



**LICENSING AUTHORITY**

Seal/Stamp

**Dr. V. G. SOMANI**  
Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health & Family Welfare  
FDA Bhawan, Koka Road, I.T.O.  
New Delhi - 110 012

Conditions of the Registration Certificate

1. The Registration Certificate shall be displayed at a prominent place by the authorised agent.
2. No drug shall be registered unless it has a free sale approval in the country of origin, and/or in other major countries.
3. The manufacturer or his authorised agent in India shall comply with the conditions of the import licence issued under the Drugs and Cosmetics Rules, 1945.
4. The manufacturer or his authorised agent in India shall inform the licensing authority forthwith in the event of any administrative action taken due to adverse reaction, viz. market withdrawal, regulatory restrictions, or cancellation of authorisation, and/or not of standard quality report of any drug pertaining to this Registration Certificate declared by the Regulatory Authority of the country of origin or by any Regulatory Authority of any other country, where the drug is marketed/sold or distributed. The despatch and marketing of the drug in such cases shall be stopped immediately, and the licensing authority shall be informed immediately. Further action in respect of such stopped marketing of drug shall be followed as per the direction of the licensing authority. In such cases, action equivalent to that taken with reference to the concerned drug in the country of origin or in the country of marketing shall be followed in India also, in consultation with the licensing authority. The licensing authority may, however, direct any further modification to this course of action, including the withdrawal of the drug from Indian market within 48 hours time period.
5. The manufacturer or his authorised agent in India shall inform the licensing authority within 30 days in writing in the event of any change in manufacturing process, or in packaging, or in labelling or in testing, or in documentation of any of the drug pertaining to this Registration Certificate. In such cases, where there shall be any major change/modification in manufacturing, or in processing or in testing, or in documentation as the case may be, at the discretion of the licensing authority, the manufacturer or his authorised agent in India shall obtain necessary approval within 30 days by submitting a separate application along with the registration fee, as specified in clause (ii) of sub rule (3) of rule 24-A.
6. The manufacturer or his authorised agent in India shall inform the licensing authority immediately in writing in the event of any change in the constitution of the firm and /or address of the registered office/ factory premises operating under this Registration Certificate. Where any such change in the constitution of the firm and/or address takes place, the current Registration Certificate shall be deemed to be valid for a maximum period of three months from the date on which the change has taken place unless, in the meantime, a fresh Registration Certificate has been taken from the licensing authority in the name of the firm with the changed constitution of the firm and/or changed address of the registered office or factory premises".



GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation  
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED  
UNDER REGISTRATION CERTIFICATE NO. FF-616  
DATED

19 JAN 2012

1. Micronized Progesterone Capsules EP/USP (100mg)
2. Micronized Progesterone Capsules EP/USP (200mg)
3.  $17\beta$ -Estradiol 0.06% Gel EP/ USP

ITEMS (Three) ONLY

Place: New Delhi


Date: 19 JAN 2012



V.G.S.  
LICENSING AUTHORITY

Seal/Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health & Family Welfare  
FDA Bhawan, KGB, E-1, I.T.O.  
New Delhi - 110 012



From :  
The Drugs Controller General (India)  
Directorate General of Health Services

FDA Bhawan, New Delhi  
Dated **19 JAN 2012**

To,

M/S. Tashima Inc  
No.2, 1st Floor, 8th Main, 2<sup>nd</sup> Cross,  
Byrasandra Layout, Jayanagar, 1st Block East,  
Bangalore-560011

Sub: -Registration of M/S. Nycomed GMBH, Robert Bosch Strasse 8,,D-78224, Singen, Germany under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

FF-505

Dear Sir,

Please refer to your application no. Nil dated 04/08/2011, received by this Office vide diary no. 36579 dated 27/07/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

8. This registration in no way relieves you of the responsibility of complying with all other provisions of the Drugs & Cosmetics Act and Rules there under, and any other provisions of any other Act and Rules applicable in the matter concerned.
9. Each consignment of the drugs to be imported by you shall be accompanied by a test / analysis reports.
10. Based on this registration, import applications for the drug (s) endorsed in the enclosed Registration Certificate shall be considered for the issue of Form 10 Licence under the Rules.
11. This Registration Certificate is being issued under the condition that during the pendency of Registration, the applicant may be required to deposit inspection fee as stipulated under Clause (5) of Rule 24-A and enable inspection of manufacturing site by the officials authorised for this purpose. Non-compliance to this condition as and when so directed would result in cancellation of Registration Certification.

Please note that Registration Certificate issued is liable to be suspended / cancelled, if any of the condition stipulated above is not complied with, apart from any other condition that may be taken under the provisions of the Drugs & Cosmetics Act, 1940 and the Rules there under.

Please acknowledge the receipt.

Yours faithfully,

V.G.S.

Drugs Controller General (India)

Copy forwarded to:

1. The Assistant Drug Controller (I), New Custom House, Annexe, Ballard Estate, Fort, Mumbai-400038.
2. The Assistant Drug Controller (I), 15/1, Strand Road, Custom House, Kolkata-700001.
3. The Assistant Drug Controller (I), Room No. 66, 2<sup>nd</sup> Floor, Custom House, Chennai-600001.
4. The Assistant Drug Controller (I), Jawaharlal Nehru Port, Trust Nhava Seva Port, Raigard, Maharashtra.
5. The Assistant Drug Controller (I), International Air Cargo Complex, Indira Gandhi International Air Port, New Delhi-110037.



GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation  
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

*Registration Certificate issued for import of drugs into India*

*Under Drugs and Cosmetics Rules, 1945*

Registration Certificate No. FF-505

19 JAN 2012 <sup>Dated</sup>

1. M/S. Nycomed GMBH, Robert Bosch Strasse 8, D-78224, Singen, Germany having factory premises at M/s. Nycomed GMBH, Robert Bosch Strasse 8, D-78224, Singen, Germany has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s) which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/04/2012 to 31/03/2015 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S Tashima Inc no:2,1st Floor, 8th Main, 2nd Cross, Byrasandra Layout, Jayanagar, 1st Block East, Bangalore-560011 who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date: 19 JAN 2012




V.G.S.  
LICENSING AUTHORITY

Seal/Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dir. General of Health Services  
Ministry of Health & Family Welfare  
FDA Bhawan, Kotia Road, I.T.O.  
New Delhi - 110 002

Conditions of the Registration Certificate

1. The Registration Certificate shall be displayed at a prominent place by the authorised agent.
2. No drug shall be registered unless it has a free sale approval in the country of origin, and/or in other major countries.
3. The manufacturer or his authorised agent in India shall comply with the conditions of the import licence issued under the Drugs and Cosmetics Rules, 1945.
4. The manufacturer or his authorised agent in India shall inform the licensing authority forthwith in the event of any administrative action taken due to adverse reaction, viz. market withdrawal, regulatory restrictions, or cancellation of authorisation, and/or not of standard quality report of any drug pertaining to this Registration Certificate declared by the Regulatory Authority of the country of origin or by any Regulatory Authority of any other country, where the drug is marketed/sold or distributed. The despatch and marketing of the drug in such cases shall be stopped immediately, and the licensing authority shall be informed immediately. Further action in respect of such stopped marketing of drug shall be followed as per the direction of the licensing authority. In such cases, action equivalent to that taken with reference to the concerned drug in the country of origin or in the country of marketing shall be followed in India also, in consultation with the licensing authority. The licensing authority may, however, direct any further modification to this course of action, including the withdrawal of the drug from Indian market within 48 hours time period.
5. The manufacturer or his authorised agent in India shall inform the licensing authority within 30 days in writing in the event of any change in manufacturing process, or in packaging, or in labelling or in testing, or in documentation of any of the drug pertaining to this Registration Certificate. In such cases, where there shall be any major change/modification in manufacturing, or in processing or in testing, or in documentation as the case may be, at the discretion of the licensing authority, the manufacturer or his authorised agent in India shall obtain necessary approval within 30 days by submitting a separate application along with the registration fee, as specified in clause (ii) of sub rule (3) of rule 24-A.
6. The manufacturer or his authorised agent in India shall inform the licensing authority immediately in writing in the event of any change in the constitution of the firm and /or address of the registered office/ factory premises operating under this Registration Certificate. Where any such change in the constitution of the firm and/or address takes place, the current Registration Certificate shall be deemed to be valid for a maximum period of three months from the date on which the change has taken place unless, in the meantime, a fresh Registration Certificate has been taken from the licensing authority in the name of the firm with the changed constitution of the firm and/or changed address of the registered office or factory premises".



F.No. 6-4/FF/22/04-DC (RE-REG 2012)


GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation  
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED  
UNDER REGISTRATION CERTIFICATE NO. FF-505  
DATED 19 JAN 2012

1. Iron Sucrose V814 Injection  
Each 5 ml Ampoule contains :  
100 mg Iron as Iron Sucrose [Iron (III) Hydroxide  
sucrose complex]
2. Iron (III) Hydroxide Polymaltose Complex Solution for  
injection Injection (I.M)  
Each 2ml Ampoule contains :  
100 mg Iron as Macromolecular [Iron (III) Hydroxide  
polymaltose complex]



ITEMS (TWO) ONLY

Place: New Delhi

Date: 19 JAN 2012



V.G.S.  
LICENSING AUTHORITY

Seal/Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health & Family Welfare  
FDA Bhawan, Kotla Road, I.T.O.  
New Delhi - 110 002



F. No. 6-3/BD/43/2011-DC

From:  
The Drugs Controller General (India)  
Directorate General of Health Services

FDA Bhawan, New Delhi

Dated:

19 JAN 2012

To,

M/S. G.C Chemie Pharmie Ltd.  
5-C, Shri Laxmi Industrial Estate,  
New Link Road, Andheri(W),  
Mumbai-400053

Sub: -Registration of M/S. Livzon New North River Pharmaceutical Co. Ltd.,  
Renmin One Road, Qingyuan City, Guangdome Province, P. R. of China under the  
Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India.

BD-1020

Dear Sir,

Please refer to your application no. Nil, dated 15/12/2011, received by this office vide diary no. 58563, dated 22/12/2011, on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall conform to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

8. This registration in no way relieves you of the responsibility of complying with all other provisions of the Drugs & Cosmetics Act and Rules there under, and any other provisions of any other Act and Rules applicable in the matter concerned.
9. Each consignment of the drugs to be imported by you shall be accompanied by a test / analysis reports.
10. Based on this registration, import applications for the drug (s) endorsed in the enclosed Registration Certificate shall be considered for the issue of Form 10 Licence under the Rules.
11. This Registration Certificate is being issued under the condition that during the pendency of Registration, the applicant may be required to deposit inspection fee as stipulated under Clause (5) of Rule 24-A and enable inspection of manufacturing site by the officials authorised for this purpose. ~~Non-compliance to this condition as and when so directed would result in cancellation of Registration Certification.~~

Please note that Registration Certificate issued is liable to be suspended / cancelled, if any of the condition stipulated above is not complied with, apart from any other condition that may be taken under the provisions of the Drugs & Cosmetics Act, 1940 and the Rules there under.

Please acknowledge the receipt.

Yours faithfully,

V.G.S

Drugs Controller General (India)

**Copy forwarded to:**

1. The Assistant Drug Controller (I), New Custom House, Annexe, Ballard Estate, Fort, Mumbai-400038.
2. The Assistant Drug Controller (I), 15/1 Strand Road, Custom House, Kolkata-700001.
3. The Assistant Drug Controller (I), Room No. 66, 2<sup>nd</sup> Floor, Custom House, Chennai-600001.
4. The Assistant Drug Controller (I), Jawaharlal Nehru Port, Trust Nhava Seva Port, Raigard, Maharashtra.
5. The Assistant Drug Controller (I), International Air Cargo Complex, Indira Gandhi International Air Port, New Delhi-110037.



GOVERNMENT OF INDIA  
Central Drugs Standard Control Organisation  
Ministry of Health & Family Welfare  
FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India

Under Drugs and Cosmetics Rules, 1945

Registration Certificate No. BD-1020

Dated  
19 JAN 2012

1. M/S. Livzon New North River Pharmaceutical Co. Ltd., China having factory premises at M/s. Livzon New North River Pharmaceutical Co. Ltd., Renmin One Road, Qingyuan City, Guangdong Province, People's Republic of China has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/01/2012 to 31/12/2014 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S G.C Chemie Pharmie Ltd., 5-C, Shri Laxmi Industrial Estate, New Link Road, Andheri(W), Mumbai-400053, who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date: 19 JAN 2012



LICENSING AUTHORITY

Seal/Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health & Family Welfare  
FDA Bhawan, Kottla Road, N.D.O.  
New Delhi - 110 002

Conditions of the Registration Certificate

1. The Registration Certificate shall be displayed at a prominent place by the authorised agent.
2. No drug shall be registered unless it has a free sale approval in the country of origin, and/or in other major countries.
3. The manufacturer or his authorised agent in India shall comply with the conditions of the import licence issued under the Drugs and Cosmetics Rules, 1945.
4. The manufacturer or his authorised agent in India shall inform the licensing authority forthwith in the event of any administrative action taken due to adverse reaction, viz. market withdrawal, regulatory restrictions, or cancellation of authorisation, and/or not of standard quality report of any drug pertaining to this Registration Certificate declared by the Regulatory Authority of the country of origin or by any Regulatory Authority of any other country, where the drug is marketed/sold or distributed. The despatch and marketing of the drug in such cases shall be stopped immediately, and the licensing authority shall be informed immediately. Further action in respect of such stopped marketing of drug shall be followed as per the direction of the licensing authority. In such cases, action equivalent to that taken with reference to the concerned drug in the country of origin or in the country of marketing shall be followed in India also, in consultation with the licensing authority. The licensing authority may, however, direct any further modification to this course of action, including the withdrawal of the drug from Indian market within 48 hours time period.
5. The manufacturer or his authorised agent in India shall inform the licensing authority within 30 days in writing in the event of any change in manufacturing process, or in packaging, or in labelling or in testing, or in documentation of any of the drug pertaining to this Registration Certificate. In such cases, where there shall be any major change/modification in manufacturing, or in processing or in testing, or in documentation as the case may be, at the discretion of the licensing authority, the manufacturer or his authorised agent in India shall obtain necessary approval within 30 days by submitting a separate application along with the registration fee, as specified in clause (ii) of sub rule (3) of rule 24-A.
6. The manufacturer or his authorised agent in India shall inform the licensing authority immediately in writing in the event of any change in the constitution of the firm and /or address of the registered office/ factory premises operating under this Registration Certificate. Where any such change in the constitution of the firm and/or address takes place, the current Registration Certificate shall be deemed to be valid for a maximum period of three months from the date on which the change has taken place unless, in the meantime, a fresh Registration Certificate has been taken from the licensing authority in the name of the firm with the changed constitution of the firm and/or changed address of the registered office or factory premises".

F. No. 6-3/BD/43/2011-DC




GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation  
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED  
UNDER REGISTRATION CERTIFICATE NO. BD-1020  
DATED

19 JAN 2012



Tobramycin IP

ITEM (One) ONLY

सत्यमेव जयते

Place: New Delhi

Date: 19 JAN 2012



V.G.S.  
LICENSING AUTHORITY

Seal/Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dir. General of Health Services  
Ministry of Health & Family Welfare  
FDA Bhawan, Kolla Road, I.T.O.  
New Delhi-110 002

